The initiation of coverage by Piper Sandler with an Overweight rating and a high price target of $45 suggests a positive outlook on Q32 Bio's stock. This is likely to generate investor interest and potentially drive the stock price up in the short term, given the credibility of Piper Sandler and the significant price target set.